Hemophagocytic syndrome and ankylosing spondylitis

封面

如何引用文章

全文:

详细

Hemophagocytic syndrome is a consequence of excessive activation of the immune system that develops as a rule in response to infection, neoplasm or as a result of an autoimmune disease leading to uncontrolled hyperinflammatory syndrome, internal injuries, cytopenia and death. The diagnosis of the syndrome is complex and is based on the criteria accepted by the society for the study of hemophagocytosis syndrome in 2004. Therapy involves the use of a combination of cytostatics and glucocorticoids and is carried out for a long time. The article describes the clinical case of hemophagocytic syndrome in a patient with ankylosing spondylitis.

作者简介

A. Belogurov

S.M. Kirov Military Medical Academy

编辑信件的主要联系方式.
Email: belogurov-ar@yandex.ru

Chair of Faculty Therapy

俄罗斯联邦, Saint Petersburg

V. Mazurov

SZGMU them. I.I. Mechnikov

Email: belogurov-ar@yandex.ru

E.E. Eyhvald Therapy and Rheumatology Department

俄罗斯联邦, Saint Petersburg

E. Tcigan

S.M. Kirov Military Medical Academy

Email: belogurov-ar@yandex.ru

Chair of Faculty Therapy

俄罗斯联邦, Saint Petersburg

V. Tyrenko

S.M. Kirov Military Medical Academy

Email: belogurov-ar@yandex.ru

Chair of Faculty Therapy

俄罗斯联邦, Saint Petersburg

M. Toporkov

S.M. Kirov Military Medical Academy

Email: belogurov-ar@yandex.ru

Chair of Faculty Therapy

俄罗斯联邦, Saint Petersburg

I. Buryak

S.M. Kirov Military Medical Academy

Email: belogurov-ar@yandex.ru

Chair of Faculty Therapy

俄罗斯联邦, Saint Petersburg

S. Voronin

S.M. Kirov Military Medical Academy

Email: belogurov-ar@yandex.ru

Chair of Faculty Therapy

俄罗斯联邦, Saint Petersburg

A. Sobolev

S.M. Kirov Military Medical Academy

Email: belogurov-ar@yandex.ru

Chair of Faculty Therapy

俄罗斯联邦, Saint Petersburg

参考

  1. Потапенко В.Г., Потихонова Н.А., Байков В.В., и др. Вторичный гемофагоцитарный синдром у взрослых в клинической практике гематолога: обзор литературы и собственные данные // Клиническая онкогематология. - 2015. - Т. 8. - № 2. - С. 169-184. [Potapenko VG, Potikhonov NA, Baikov VV, et al. Secondary hemophagocytic syndrome in adults in the clinical practice of a hematologist: a review of the literature and proprietary data. Clinical Oncohematology. 2015;8(2):169-184. (In Russ.)]
  2. Масчан М.А., Новичкова Г.А. Гемофагоцитарный лимфогистиоцитоз // Вопросы современной педиатрии. - 2009. - Т. 8. - № 3. - С. 66-75. [Maschan MA, Novichkova GA. Hemophagocytic lymphogystyocytosis. Issues of modern pediatrics. 2009;8(3):66-75. (In Russ.)]
  3. Janka GE. Familial and acquired hemophagocytic ymphohistiocytosis. Eur J Pediatr. 2007;166(2):95-109.
  4. Favara BE. Hemophagocytic lymphohistiocytosis: a hemophagocytic syndrome. Semin Diagn Pathol. 1992;9(1):63-74.
  5. Масчан М.А., Полтавец Н.В. Гемофагоцитарный синдром в неотложной и интенсивной педиатрии // Педиатрическая фармакология. - 2011. - Т. 8. - № 2. - С. 15-21. [Maschan MA, Poltavec NV Gemofagocitarnyj sindrom v neotlozhnoj i intensivnoj pediatrii. Pediatricheskaya farmakologiya. 2011;8(2):15-21. (In Russ.)]
  6. Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol. 2003;15(5):587-590.
  7. Morris JA, Adamson AR, Holt PJ. Still’s disease and the virus associated haemophagocytic syndrome. Ann Rheum Dis. 1985;44(5):349-353.
  8. Prieur AM, Fischer A, Griscelli C. Still’s disease and haemophagocytic syndrome. Ann Rheum Dis. 1985;44(11):806.
  9. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125(19):2908-2914. doi: 10.1182/blood-2015-01- 551622.
  10. Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28(2):277-292. doi: 10.1016/j.berh.2014.03.002.
  11. Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 suppl):82-89. doi: 10.1016/j.bbmt.2009.11.014.
  12. Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of hemophagocytic lymphohistiocytosis. Br J Haematol. 2001;114:761-9.
  13. Масчан М.А., Новичкова Г.А. Федеральные клинические рекомендации по диагностике и лечению гемофагоцитарного лимфогистиоцитоза. - М., 2014. [Maschan MA, Novichkova GA. Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu gemofagocitarnogo limfogistiocitoza. Moscow; 2014. (In Russ.)]
  14. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002;44(3):259-272.
  15. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140(3):221-230.
  16. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052. doi: 10.1182/blood-2011-03- 278127.
  17. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21(5):245-53. doi: 10.1016/j.blre.2007.05.001.
  18. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991;18(1):29-33.
  19. Esumi N, Ikushima S, Todo S, et al. Hyperferritinemia in malignant histiocytosis, virus-associated hemophagocytic syndrome and familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1989;78:268-270.
  20. Ladisch S, Poplack DG, Holiman B, et al. Immunodeficiency in familial erythrophagocytic lymphohistiocytosis. Lancet. 1978;1:581-583.
  21. Perez N, Virelizier J, Arenzana-Seisdedos F, et al. Impaired natural killer cell activity in lymphohistiocytosis syndrome. J Pediatr. 1984;104:569-573.
  22. Sullivan KE, Delaat CA, Douglas SD, et al. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res. 1998;44:465-468. doi: 10.1203/00006450-199810000-00001.
  23. Kogawa K, Lee SM, Villanueva J, et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99:61-66.
  24. Schneider EM, Lorenz I, Müller-Rosenberger M, et al. Hemophagocytic lymphohistiocytosis (HLH) is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer cell induced apoptosis. Blood. 2002;100:2891-2898.
  25. Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood. 1989;73:2128-2132.
  26. Henter J-I, Elinder G, Söder O, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78:2918-2922.
  27. Horne AC, Zheng C, Lorenz I, et al. Subtyping of natural killer cell cytotoxicity deficiencies in hemophagocytic lymphohistocytosis provides therapeutic guidance. Br J Haematol. 2005;129:658-666.
  28. Trottestam H, Horne A, Aricó M, et al. Chemoimmunotherapy for hematophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4573-4584. doi: 10.1182/blood-2011-06-356261.
  29. Henter J, Horne A, Aricó M, et al. HLH-2004: Diagnostic and Therapetuic Guidelines for Hemophagocytic Liphohistiocytosis. Pediatr Blood Cancer. 2007;48(124):124-131. doi: 10.1002/pbc.21039.

版权所有 © Belogurov A.R., Mazurov V.I., Tcigan E.N., Tyrenko V.V., Toporkov M.M., Buryak I.S., Voronin S.V., Sobolev A.V., 2018

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

##common.cookie##